Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss Veru (NASDAQ: VERU) enrolled the first patient in the Phase 2b PLATEAU trial testing oral enobosarm 3mg plus injectable semaglutide in ~200 older patients (age ≥65, BMI ≥35) with obesity to preserve lean mass, physical function and bone while augmenting fat and weight loss.An interim DXA analysis is expected in Q1 2027 (34 weeks) and final topline data in Q4 2027 (primary endpoint: percent change in total body weight at 68 weeks).

#VERU Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

www.stocktitan.net/news/VERU/veru-enrolls-f...

Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress -- Incremental weight loss is an acceptable approvable primary endpoint with key secondary endpoints on physical function and body

#VERU Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress

www.stocktitan.net/news/VERU/veru-reports-f...

Veru Announces Pricing of $25 Million Public Offering Veru (NASDAQ: VERU)Oct 30, 2025 consisting of 1,400,000 common shares, pre-funded warrants for up to 7,000,000 shares, and accompanying Series A and Series B warrants to purchase up to 8,400,000 shares each.The combined public offering price per share with warrants is $3.00 (pre-funded combined price $2.999). Gross proceeds are expected to be approximately $25.2 million at closing (on or about Oct 31, 2025); cash exercise of all warrants would yield an additional $50.4 million. Net proceeds are planned to fund development of enobosarm, primarily the Phase 2b PLATEAU clinical study, and for working capital and general corporate purposes.

#VERU Veru Announces Pricing of $25 Million Public Offering

www.stocktitan.net/news/VERU/veru-announces...

Veru Announces Proposed Public Offering Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, announced today that it has commenced an underwritten public offering

#VERU Veru Announces Proposed Public Offering

www.stocktitan.net/news/VERU/veru-announces...

Leading Indicators, Tuesday September 23, 2025 – Crystal Equity Research

Small-cap stocks with declining money flow, Tue Sept 23rd - #VERU #UPXI #TEAD #SATL #REAX #QURE #PRAA #OFS #MAXN #LIDR #GLTO #FIP #ENTA #DNUT #CLYM #WGO #TFIN #SKIL #NIC #LANV #EVH #CCS #BHE - More: crystalequityresearch.com/leading-indi... - #smallcap

Trade Alerts, Thursday August 14, 2025 – Crystal Equity Research

Small-cap stocks oversold with improving relative strength, Thu Aug 14th - #VERU #HIMX #DMLP - More: crystalequityresearch.com/trade-alerts... - #smallcap

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress Veru Inc. (NASDAQ: VERU) reported positive results from its Phase 2b QUALITY study evaluating enobosarm in combination with semaglutide for weight loss management. The study showed that enobosarm 3mg + semaglutide achieved 100% preservation of lean mass compared to placebo + semaglutide at 16 weeks (p100% fat mass loss versus 66% for placebo + semaglutide.In the Maintenance Extension study, enobosarm 3mg reduced body weight regain by 46% after semaglutide discontinuation. The company also announced a novel modified release oral enobosarm formulation with patent protection through 2046. For Q3 2025, Veru reported reduced operating losses of $7.5 million compared to $10.5 million year-over-year, with cash reserves of $15.0 million as of June 30, 2025.

#VERU Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

www.stocktitan.net/news/VERU/veru-reports-f...

Revolutionary Drug Delivery Technology Transforms Veru's Enobosarm Treatment: New Formulation Shows Promising Results Laxxon's SPID technology enables advanced oral drug delivery for Veru's enobosarm, achieving optimal release profile and enhanced bioavailability. Learn more details.

#VERU Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s Enobosarm, Utilizing Laxxon’s SPID®-Technology

www.stocktitan.net/news/VERU/laxxon-medical...

JUST IN: ( NASDAQ: #VERU ) Veru Selects Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Study

Just In: ( NASDAQ: #VERU ) Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study Veru Inc. (NASDAQ: VERU) has successfully developed a novel modified release oral formulation for enobosarm, a selective androgen receptor modulator targeted for chronic weight loss management. The company completed a single dose, open label pilot study that confirmed the desired pharmacokinetic profile of the new 3mg formulation.The study demonstrated key improvements including reduced maximum plasma concentration, delayed time to maximum plasma concentration, and a distinct secondary peak plasma concentration, while maintaining similar absorption compared to immediate release capsules. The formulation, developed in partnership with Laxxon Medical using SPID®-Technology, is protected by patents through 2037, with new patent applications potentially extending protection until 2046.

#VERU Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

www.stocktitan.net/news/VERU/veru-announces...

1208 Fiċ-Ċilì, l-akbar 1% tal-kumpaniji jirrappreżentaw 88% tal-bejgħ. Fiċ-Ċilì, l-akbar 1% tal-kumpaniji jirrappreżentaw 88% tal-bejgħ.#VERU Din hija waħda mid-dejta ppreżentata mill-ġurnalist Daniel Matamala fil-kolonna tal-opinjoni tiegħu "Ħallas Aħjar," ippubblikata fil-gazzetta La Tercera, b'reazzjoni għall-isfida tal-Ministru tax-Xogħol Jeanette Jara lill-komunità tan-negozju, bil-frażi: "Jekk verament trid l-inklużjoni, ħallas aħjar." L-opinjoni ta' Matamala qanqlet dibattitu li fih ipparteċipa wkoll l-ekonomista Sebastián Claro, li ppubblika kolonna oħra f'El Mercurio intitolata "Ħallas Aħjar, Po." Aħna vverifikajna l-fatti tad-dejta u d-dikjarazzjonijiet imqajma miż-żewġ kolonnisti. Il-kuntest Fit-13 ta’ Marzu, il-programm ta’ diskussjoni Red Activa fuq Pulso La Tercera, flimkien ma’ Chile Mujeres , stieden lill-Ministru tax-Xogħol, Jeannette, lil Bernardo Larraín Matte, eks kap tas-Sociedad de Fomento Fabril (SOFOFA), u lil Ricardo Mewes, president tas-CPC. L-għan tal-laqgħa kien li jiġu diskussi l-isfidi li d-dinja tan-negozju qed jiġu ppreżentati mil-liġijiet il-ġodda dwar il-konċiljazzjoni , it-tnaqqis tal-ġurnata tax-xogħol— il-liġi ta’ 40 siegħa— , il-vjolenza fuq il-post tax-xogħol, il-fastidju fuq il-post tax-xogħol, u l-fastidju sesswali— il-Liġi Karin . Il-qsim Id-differenzi ħarġu meta Larraín qal li s-suq jiddetermina s-salarji u li dan iżid il-produttività tan-negozju. Il-Ministru Jara wieġeb: "Jekk verament trid l-inklużjoni, ħallas aħjar. Irrispetta aktar id-drittijiet tan-nies. Dak hu wkoll ir-rwol ta' min iħaddem. Jekk in-nies ma jistgħux ikomplu jgħixu kif inhuma, mhux se jkollhom biżżejjed biex jgħixu." Parti mid-djalogu tista' tinstab fuq EMOL . Il-kolonna ta' Daniel Matamala Fis-17 ta' Marzu, il-gazzetta La Tercera ppubblikat il-kolonna " Paguen Mejor" (Ħallas Aħjar ), fejn Daniel Matamala jiddikjara li "l-ekonomija Ċilena hija tant ikkonċentrata li l-akbar 1% tal-kumpaniji jirrappreżentaw 88% tal-bejgħ." Ikkuntattjajna lill-ġurnalist u staqsejnieh minn fejn ġiet din id-dejta. "Hija l-informazzjoni rrappurtata sena wara sena mill-Internal Revenue Service," qal. Aċċessajna r-rapport "Management and Statistics" tas-SII u analizzajna r-rapporti tal-bejgħ għall-kumpaniji skont id-daqs. L-aktar database reċenti hija mill-2022 . Dik is-sena, ġew irreġistrati total ta' 1,508,032 kumpanija, li minnhom 18,630 waqgħu fil-kategorija "kumpaniji kbar". Kif jirrimarka l-kolonista, dan in-numru jikkorrispondi għal 1% tat-total tal-pajjiż (1.2% biex inkunu eżatti). Dan il-grupp ta' kumpaniji rreġistra bejgħ ta' 32,042,606,705 UF minn total nazzjonali ta' 36,293,730,057 UF. Dawn l-ammonti jirrappreżentaw eżattament 88%. Iċ-ċifra pprovduta minn Daniel Matamala fil-kolonna tiegħu hija #VERA. Matamala jsemmi wkoll xi inizjattivi li tnedew matul l-inkwiet soċjali rigward kwistjonijiet tas-salarji. Waħda minnhom hija Desafío 10X , fondazzjoni li tfittex li tnaqqas id-differenza bejn is-salarji minimi u massimi fil-kumpaniji. Fi kliem sempliċi, l-ogħla salarji fl-istess organizzazzjoni m'għandhomx jaqbżu l-10 darbiet l-aktar baxxi. Tkellimna ma' Sebastián Martínez, Direttur Eżekuttiv ta' Desafío 10X, u ċċekkjajna l-istatus ta' dan il-proġett. "Naqblu ma' dak li jipproponi Matamala fil-kolonna tiegħu, iżda l-mod kif jippreżentana jagħmilha tidher li ħadem biss matul dak il-mument, u dan mhux il-każ. Għadna preżenti, aħna ħajjin," jgħid Martínez. Bħalissa, 2,318-il kumpanija huma rreġistrati mal-inizjattiva, li għandha l-għan li tipprovdi valur addizzjonali lill-membri tagħha b'aċċess għal workshops iffukati fuq oqsma speċifiċi tal-kumpanija, u b'hekk tiġġenera interess fit-titjib tas-salarji tal-impjegati u l-produttività tan-negozju. Il-fondazzjoni bħalissa qed tħejji ittra lill-editur ta' La Tercera biex taqsam ir-rispons u l-opinjoni tagħha dwar il-kolonna ta' Daniel Matamala. Sebastian Claro L-ekonomista u eks viċi president tal-Bank Ċentrali, Sebastián Claro, esprima l-opinjoni tiegħu fil-gazzetta El Mercurio, bil-kolonna " Paguen mejor, po ." Huwa jgħid: "Il-pagi reali fiċ-Ċilì żdiedu b'medja ta' 2.2% fis-sena matul l-aħħar 40 sena." Biex nivverifikaw din id-dejta, tkellimna ma' Ricardo Ubeda, ekonomista fl-Università Adolfo Ibáñez, li l-ewwel iċċara li l-pagi reali jirreferu għall-poter tal-akkwist tal-pagi u għalhekk huma affettwati mill-inflazzjoni. Imbagħad wieġeb li "dan huwa korrett, u huwa għaliex il-produttività ma kibritx, u magħha, il-pagi reali ma jistgħux jikbru." Id-dejta ta' Sebastián Claro hija #VERA. Fil-kolonna tiegħek issemmi li l-eks president tas-Soċjetà għall-Iżvilupp Industrijali (SOFOFA), Alfonso Swett, appella għal patt soċjali ġdid. Stajna nivverifikaw li dan huwa VERU. Swett ta intervista fuq Radio Duna fejn iddikjara l-ħtieġa għal patt soċjali ġdid u li t-tkabbir ekonomiku mingħajr tkabbir fil-pagi huwa tkabbir fuq medda qasira ta’ żmien. L-intervista bir-radju tista’ tinstab fl-artiklu ppubblikat minn El Diario Financiero . Aqsamha:

ICYMI: 1208: Fiċ-Ċilì, l-akbar 1% tal-kumpaniji jirrappreżentaw 88% tal-bejgħ.

Fiċ-Ċilì, l-akbar 1% tal-kumpaniji jirrappreżentaw 88% tal-bejgħ.#VERU

Din hija waħda mid-dejta ppreżentata mill-ġurnalist Daniel Matamala fil-kolonna… #ĦallasAħjar #Inklużjoni #Negozju #Ekonómija #Dibattitu

1208 Fiċ-Ċilì, l-akbar 1% tal-kumpaniji jirrappreżentaw 88% tal-bejgħ. Fiċ-Ċilì, l-akbar 1% tal-kumpaniji jirrappreżentaw 88% tal-bejgħ.#VERU Din hija waħda mid-dejta ppreżentata mill-ġurnalist Daniel Matamala fil-kolonna tal-opinjoni tiegħu "Ħallas Aħjar," ippubblikata fil-gazzetta La Tercera, b'reazzjoni għall-isfida tal-Ministru tax-Xogħol Jeanette Jara lill-komunità tan-negozju, bil-frażi: "Jekk verament trid l-inklużjoni, ħallas aħjar." L-opinjoni ta' Matamala qanqlet dibattitu li fih ipparteċipa wkoll l-ekonomista Sebastián Claro, li ppubblika kolonna oħra f'El Mercurio intitolata "Ħallas Aħjar, Po." Aħna vverifikajna l-fatti tad-dejta u d-dikjarazzjonijiet imqajma miż-żewġ kolonnisti. Il-kuntest Fit-13 ta’ Marzu, il-programm ta’ diskussjoni Red Activa fuq Pulso La Tercera, flimkien ma’ Chile Mujeres , stieden lill-Ministru tax-Xogħol, Jeannette, lil Bernardo Larraín Matte, eks kap tas-Sociedad de Fomento Fabril (SOFOFA), u lil Ricardo Mewes, president tas-CPC. L-għan tal-laqgħa kien li jiġu diskussi l-isfidi li d-dinja tan-negozju qed jiġu ppreżentati mil-liġijiet il-ġodda dwar il-konċiljazzjoni , it-tnaqqis tal-ġurnata tax-xogħol— il-liġi ta’ 40 siegħa— , il-vjolenza fuq il-post tax-xogħol, il-fastidju fuq il-post tax-xogħol, u l-fastidju sesswali— il-Liġi Karin . Il-qsim Id-differenzi ħarġu meta Larraín qal li s-suq jiddetermina s-salarji u li dan iżid il-produttività tan-negozju. Il-Ministru Jara wieġeb: "Jekk verament trid l-inklużjoni, ħallas aħjar. Irrispetta aktar id-drittijiet tan-nies. Dak hu wkoll ir-rwol ta' min iħaddem. Jekk in-nies ma jistgħux ikomplu jgħixu kif inhuma, mhux se jkollhom biżżejjed biex jgħixu." Parti mid-djalogu tista' tinstab fuq EMOL . Il-kolonna ta' Daniel Matamala Fis-17 ta' Marzu, il-gazzetta La Tercera ppubblikat il-kolonna " Paguen Mejor" (Ħallas Aħjar ), fejn Daniel Matamala jiddikjara li "l-ekonomija Ċilena hija tant ikkonċentrata li l-akbar 1% tal-kumpaniji jirrappreżentaw 88% tal-bejgħ." Ikkuntattjajna lill-ġurnalist u staqsejnieh minn fejn ġiet din id-dejta. "Hija l-informazzjoni rrappurtata sena wara sena mill-Internal Revenue Service," qal. Aċċessajna r-rapport "Management and Statistics" tas-SII u analizzajna r-rapporti tal-bejgħ għall-kumpaniji skont id-daqs. L-aktar database reċenti hija mill-2022 . Dik is-sena, ġew irreġistrati total ta' 1,508,032 kumpanija, li minnhom 18,630 waqgħu fil-kategorija "kumpaniji kbar". Kif jirrimarka l-kolonista, dan in-numru jikkorrispondi għal 1% tat-total tal-pajjiż (1.2% biex inkunu eżatti). Dan il-grupp ta' kumpaniji rreġistra bejgħ ta' 32,042,606,705 UF minn total nazzjonali ta' 36,293,730,057 UF. Dawn l-ammonti jirrappreżentaw eżattament 88%. Iċ-ċifra pprovduta minn Daniel Matamala fil-kolonna tiegħu hija #VERA. Matamala jsemmi wkoll xi inizjattivi li tnedew matul l-inkwiet soċjali rigward kwistjonijiet tas-salarji. Waħda minnhom hija Desafío 10X , fondazzjoni li tfittex li tnaqqas id-differenza bejn is-salarji minimi u massimi fil-kumpaniji. Fi kliem sempliċi, l-ogħla salarji fl-istess organizzazzjoni m'għandhomx jaqbżu l-10 darbiet l-aktar baxxi. Tkellimna ma' Sebastián Martínez, Direttur Eżekuttiv ta' Desafío 10X, u ċċekkjajna l-istatus ta' dan il-proġett. "Naqblu ma' dak li jipproponi Matamala fil-kolonna tiegħu, iżda l-mod kif jippreżentana jagħmilha tidher li ħadem biss matul dak il-mument, u dan mhux il-każ. Għadna preżenti, aħna ħajjin," jgħid Martínez. Bħalissa, 2,318-il kumpanija huma rreġistrati mal-inizjattiva, li għandha l-għan li tipprovdi valur addizzjonali lill-membri tagħha b'aċċess għal workshops iffukati fuq oqsma speċifiċi tal-kumpanija, u b'hekk tiġġenera interess fit-titjib tas-salarji tal-impjegati u l-produttività tan-negozju. Il-fondazzjoni bħalissa qed tħejji ittra lill-editur ta' La Tercera biex taqsam ir-rispons u l-opinjoni tagħha dwar il-kolonna ta' Daniel Matamala. Sebastian Claro L-ekonomista u eks viċi president tal-Bank Ċentrali, Sebastián Claro, esprima l-opinjoni tiegħu fil-gazzetta El Mercurio, bil-kolonna " Paguen mejor, po ." Huwa jgħid: "Il-pagi reali fiċ-Ċilì żdiedu b'medja ta' 2.2% fis-sena matul l-aħħar 40 sena." Biex nivverifikaw din id-dejta, tkellimna ma' Ricardo Ubeda, ekonomista fl-Università Adolfo Ibáñez, li l-ewwel iċċara li l-pagi reali jirreferu għall-poter tal-akkwist tal-pagi u għalhekk huma affettwati mill-inflazzjoni. Imbagħad wieġeb li "dan huwa korrett, u huwa għaliex il-produttività ma kibritx, u magħha, il-pagi reali ma jistgħux jikbru." Id-dejta ta' Sebastián Claro hija #VERA. Fil-kolonna tiegħek issemmi li l-eks president tas-Soċjetà għall-Iżvilupp Industrijali (SOFOFA), Alfonso Swett, appella għal patt soċjali ġdid. Stajna nivverifikaw li dan huwa VERU. Swett ta intervista fuq Radio Duna fejn iddikjara l-ħtieġa għal patt soċjali ġdid u li t-tkabbir ekonomiku mingħajr tkabbir fil-pagi huwa tkabbir fuq medda qasira ta’ żmien. L-intervista bir-radju tista’ tinstab fl-artiklu ppubblikat minn El Diario Financiero . Aqsamha:

1208: Fiċ-Ċilì, l-akbar 1% tal-kumpaniji jirrappreżentaw 88% tal-bejgħ.

Fiċ-Ċilì, l-akbar 1% tal-kumpaniji jirrappreżentaw 88% tal-bejgħ.#VERU

Din hija waħda mid-dejta ppreżentata mill-ġurnalist Daniel Matamala fil-kolonna tal-opinjoni tiegħu… #ĦallasAħjar #Ekonomija #Inklużjoni #Bejgħ #Malta

Veru Takes Critical Step to Maintain Nasdaq Listing with 1-for-10 Reverse Split Veru implements strategic reverse split starting August 8. New 1:10 ratio aims to boost share price above Nasdaq minimum. See how this affects your holdings.

#VERU Veru Announces Reverse Stock Split

www.stocktitan.net/news/VERU/veru-announces...

A smiling woman measuring her waist with a blue tape measure in front of a mirror, reflecting her progress.

Big news from #Veru_Pharma (Nasdaq: #VERU)! The enobosarm + semaglutide combo not only torches fat with 99% weight loss from fat alone—it also preserves muscle and reduces nasty GI side effects. Phase 3, here we come!
prismmarketview.com/veru-reports...

Mid-day market movers!
#Veru_Pharma ( #VERU) Gains 17% on Positive Safety Data for Enobosarm + Semaglutide Combo
#Incannex ( #IXHL) Drops 15% Despite Strategic Warrant Cancellation
prismmarketview.com/prism-mid-da...

Veru Participates in a Virtual Investor KOL Connect Segment Veru Inc. (NASDAQ: VERU) has released a Virtual Investor KOL segment featuring obesity expert Louis J. Aronne, MD, FACP. The segment includes a discussion between Dr. Aronne and Veru's President, CEO, and Founder, Mitchell Steiner, M.D., F.A.C.S, focusing on obesity and GLP-1s, current treatment landscape, and unmet needs in the field. The discussion also highlights Veru's lead program, the Enobosarm Phase 2b QUALITY study, and reviews the company's latest topline clinical data.

#VERU Veru Participates in a Virtual Investor KOL Connect Segment

www.stocktitan.net/news/VERU/veru-participa...

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress Veru Inc. (NASDAQ: VERU) reported fiscal Q2 2025 results and clinical progress for its enobosarm program. The company's Phase 2b QUALITY study showed positive results in combining enobosarm with GLP-1 RA drugs, demonstrating significant benefits in fat loss while preserving lean mass. Key findings include a 71% reduction in lean mass loss and improved body composition, with the 3mg dose showing >99% preservation of lean mass. The study revealed that enobosarm + semaglutide resulted in more selective fat loss (90.6%) compared to placebo + semaglutide (68%). Physical function tests showed significant improvements, with a 54.4% reduction in patients experiencing physical decline. Veru expects unblinded safety data and extension study results in Q2 2025, followed by an FDA End of Phase 2 meeting in Q3 2025. The company reported a net loss of $7.9 million ($0.05 per share) for Q2 2025.

#VERU Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

www.stocktitan.net/news/VERU/veru-reports-f...

Game-Changing Clinical Results: Veru's Drug Outperforms Weight Loss Giant Wegovy in Muscle Protection Veru reports successful Phase 2b results with 71% lean mass reduction, sells FC2 business for $18M, and advances new cardiometabolic program amid increased R&D investment.

#VERU Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

www.stocktitan.net/news/VERU/veru-reports-f...

NEWS: ( NASDAQ: #VERU ) Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY (Semaglutide) for Weight Reduction

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction Veru (NASDAQ: VERU) announced positive topline results from its Phase 2b QUALITY clinical study evaluating enobosarm in combination with WEGOVY (semaglutide) for weight reduction. The study met its primary endpoint, demonstrating that enobosarm significantly preserved lean mass in patients receiving WEGOVY, with treated patients losing 71% less lean mass than those on WEGOVY alone.Key findings include: patients on enobosarm lost 27% more fat mass than the control group, maintained similar total body weight loss, and showed reduced decline in physical function. The study involved 168 older patients (>60 years) over 16 weeks. In the placebo group, 32% of total weight loss was lean mass, while 42.6% experienced significant decline in stair climb power, compared to only 19.4% in the enobosarm group.The company plans to proceed with Phase 3 trials following these positive results, with an anticipated sample size of 470 subjects over 52 weeks.

#VERU Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

www.stocktitan.net/news/VERU/veru-announces...

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

Weekly Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #IPA 258% OTM
2. #MSTR 65% OTM
3. #GME 50% OTM
4. #VERU 45% OTM
5. #NIO 43% OTM

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#GME, #VERU, #NIO, #NAK, #TEM

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #GME 121% OTM
2. #MSTR 67% OTM
3. #VERU 45% OTM
4. #NIO 43% OTM
5. #NAK 38% OTM

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#PLTR, #VERU, #NAK, #NFLX, #QUBT

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

AM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #PLTR 65% OTM
2. #MSTR 57% OTM
3. #VERU 45% OTM
4. #NAK 38% OTM
5. #NVDA 31% OTM

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CLW, #BITX, #MSTX, #VERU, #UPST

#OptionFlow #OptionsTrading #Trading

Veru Sells FC2 Female Condom Business for $18M, Shifts Focus to Biopharma Development Veru transforms into pure biopharmaceutical company through $18M FC2 business sale, cuts workforce by 90% while advancing enobosarm clinical trials for weight management.

#VERU Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

www.stocktitan.net/news/VERU/veru-announces...

Just In: ( NASDAQ: #VERU ) Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

#StockMarket #News

#VERU Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

www.stocktitan.net/news/VERU/veru-to-presen...